Advancing In Vivo DNA Delivery Platforms to Enable Durable & Controllable Immune Reset

• Evaluating DNA-based delivery approaches against RNA and viral systems to achieve more sustained yet controllable immune cell modification for autoimmune applications
• Exploring strategies to balance transient versus integrating expression to optimize durability while minimizing long-term safety concerns
• Leveraging complex cargo design including multi-target and dual CAR approaches to address immune reset alongside disease-specific drivers such as fibrosis

Speakers:

Edward Rebar

Chief Scientific Officer

CPTx